

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

MTA Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs [ID579]

Batch 41

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Scoping workshop attendees agreed that it was important to consider those who may have difficulty self-administering subcutaneous treatments, for example those with very severe disease or those with needle-phobia.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Scoping workshop attendees agreed that the Committee should consider these concerns, however it was unlikely that anything would need to be specifically addressed, as there are already processes in place in clinical practice for people who are unable to self-administer subcutaneous treatments.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Scoping workshop attendees agreed that no change was required in the scope as there are already processes in place for people who are unable to

self-administer subcutaneous treatments.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders related to potential equalities issues have been added to the matrix

Approved by Associate Director (name): Helen Knight

Date: 23/10/2015